Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.30 |
| ▸ | STK10 | O94804 | 2/20 | 0.30 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.30 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26160500 | 1.00 | GRM5 (0.40) | GRM5MRGPRX4TNFMAOBMAOA | |
| SCHEMBL26160482 | 0.91 | MAOB (0.37) | GRM5MAOBLTB4RLTB4R2 | |
| SCHEMBL26160493 | 0.91 | MAOB (0.37) | GRM5MAOBLTB4RLTB4R2 | |
| SCHEMBL26160488 | 0.91 | MAOB (0.37) | GRM5MAOBLTB4RLTB4R2 | |
| SCHEMBL23905970 | 0.90 | GRM5 (0.39) | GRM5MRGPRX4TNFMAOBMAOA | |
| SCHEMBL30251017 | 0.90 | GRM5 (0.39) | GRM5MRGPRX4TNFMAOBMAOA | |
| SCHEMBL26159421 | 0.90 | GRM5 (0.39) | GRM5MRGPRX4TNFMAOBMAOA | |
| SCHEMBL23882869 | 0.90 | GRM5 (0.39) | GRM5MRGPRX4TNFMAOBMAOA | |
| SCHEMBL23906321 | 0.90 | GRM5 (0.39) | GRM5TNFMAOBMAOA | |
| SCHEMBL23905983 | 0.86 | MAOB (0.35) | GRM5MRGPRX4MAOBLTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | GRM5 2303/4885MRGPRX4 124/4885TNF 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.